Trials / Completed
CompletedNCT00426803
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Parallel Groups, Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | activated recombinant human factor VII |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2004-06-01
- Completion
- 2004-06-01
- First posted
- 2007-01-25
- Last updated
- 2017-01-18
Locations
15 sites across 15 countries: Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Italy, Netherlands, Norway, Singapore, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00426803. Inclusion in this directory is not an endorsement.